Page last updated: 2024-12-05

methylpentynol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

methylpentynol: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6494
CHEMBL ID501613
CHEBI ID134752
MeSH IDM0045370

Synonyms (144)

Synonym
nsc28797
nsc-28797
LS-11587
einecs 201-055-5
ai3-37931
methylpentynol [inn:ban]
brn 0969340
2-ethinylbutanol-2
3-methyl-1-pentyn-2-ol
methylpentynolum [inn-latin]
olfine p
alpha-ethyl-alpha-methylpropargyl alcohol
3-metil-pentin-3-ol [italian]
methylpentinol
metilpentinol [inn-spanish]
(+-)-3-methylpent-1-yn-3-ol
3-methyl-pentin-(1)-ol-(3) [german]
nsc 28797
ethyl ethynyl methyl carbinol
metilpentinolo [dcit]
methylpentynol
3-methylpentin-3-ol
ai3-14502
D07332
atemorin (tn)
methylpentynol (inn)
oblevil
dormalest
olosot
sedapercut
util
3-methyl-1-pentyn-3-ol
pentinol
methylparafynol
2-butanol, 2-ethynyl-
pentadorm
apridol
hexofen
methylethylethynylcarbinol
mecarol
3-methyl-1-pentynol
3-methylpent-1-yn-3-ol
methylpentynolum
methylethylacetylenylcarbinol
citodorm
seral
pentydorm
.alpha.-ethyl-.alpha.-methylpropargyl alcohol
nsc-975
2-ethinylbutanol
riposon
olvadon
formison
dormiphen
sonnormon
atempol
aniphor
3-methylpentyn-3-ol
dormison
dormosan
1-pentyn-3-ol, 3-methyl-
insomnol
dorison
sintyal
BDH ,
pentyrest
oblivon
imnudorm
methylpentanol
77-75-8
allotropal
ethinylmethylethylcarbinol
mepentil
hesofen
macarol
anti-stress
dormidin
nsc975
2-ethinyl butanol-2
somnesin
perlopal
dormocit
meparfynol
metilparafinolo
pentydrom
melpintol
noxokratin
miramel
m-pentynol
dormigen
n-oblivon
metilpentinolo
2-ethynyl-2-butanol
atemorin
dalgol
wln: qx2&1&1uu1
comesa
NCGC00166025-01
3-methyl-1-pentyn-3-ol, 98%
CHEBI:134752
CHEMBL501613
M0396
HMS3264A21
AKOS009158777
4-01-00-02242 (beilstein handbook reference)
metilpentinol
ec 201-055-5
3-methyl-pentin-(1)-ol-(3)
3-metil-pentin-3-ol
unii-b017bc5b1n
b017bc5b1n ,
tox21_112294
dtxcid401756
cas-77-75-8
dtxsid5021756 ,
meparfylon
FT-0616042
methylpentynol [mart.]
(+/-)-3-methylpent-1-yn-3-ol
methylpentynol [inn]
meparfynol [mi]
methylpentynol [who-dd]
CCG-214047
3-methyl-1-pentin-3-ol
ethynylethylmethylcarbinol
3-methyl-1-pentyne-3-ol
(.+/-.)-3-methylpent-1-yn-3-ol
pent-1-yne-3-ol, 3-methyl-
3-hydroxy-3-methyl-1-pentyne
methylpentinolum
AB01563255_01
mfcd00004479
SR-01000944285-1
sr-01000944285
Q412090
DB13733
BRD-A11662333-001-01-7
AMY4108
D91328
3-methyl-1-pentyn-3-ol methyl pentynol
NCGC00166025-02
EN300-104662
ethyl ethynyl methyl carbinol, meparfynol
Z1251192957

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"A titrimetric method is described for the determination of three acetylenic hypnotics, namely ethchlorvynol, ethinamate, and methylpentynol carbamate, in bulk and in dosage forms."( Titrimetric determination of acetylenic hyponotics using organic brominating agents.
Belal, F; el-Brashy, A; Rizk, M; Walash, MI, 1988
)
0.48
"Titrimetric and spectrophotometric titration methods are described for the quantitative determination of acetylenic hypnotics ethchlorvynol, ethinamate, and meparfynol carbamate as pure substances and in dosage forms."( Titrimetric and spectrophotometric determination of acetylenic hypnotics, using brominating agents.
el-Brashy, A; Rizk, MS; Walash, MI,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ynoneAn alpha,beta-unsaturated ketone of general formula R(1)C#C-C(=O)R(2) (R(2) =/= H) in which the aldehydic C=O function is conjugated to a C#C triple bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
TDP1 proteinHomo sapiens (human)Potency0.00080.000811.382244.6684AID686978
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (25)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-199058 (92.06)18.7374
1990's1 (1.59)18.2507
2000's1 (1.59)29.6817
2010's2 (3.17)24.3611
2020's1 (1.59)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.52%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other65 (98.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]